A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder

References

• Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809–16
   PubMed Web of Science ®Google Scholar
• Michaud CM, Murray CJL, Bloom BR. Burden of disease: implications for future research. J Am Med Assoc 2001;285: 535–9
   Google Scholar
• Angst J. Epidemiology of depression. Psychopharmacology 1992;106:S71–S74
   PubMed Web of Science ®Google Scholar
• Corruble E, Puech A. How to improve the risk–benefit ratio of antidepressants. Int Clin Psychopharmacol 1993;8:237–41
   PubMed Web of Science ®Google Scholar
• Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 1992;149:795–800
   PubMed Web of Science ®Google Scholar
• Kasper S. Rationale for long-term antidepressant therapy. Int Clin Psychopharmacol 1993;8:225–35
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Comparison of the tolerability of nefazodone, imipramine, fluoxetine, sertraline, paroxetine, and venlafaxine. J Clin Psychiatry 1995;56(Suppl 6):12–21
   PubMed Web of Science ®Google Scholar
• Murdoch D, McTavish D. Sertraline: a review of its pharmaco-dynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive–compulsive disorder. Drugs 1992;44:604–24
   PubMed Web of Science ®Google Scholar
• Lydiard RB, Stahl SM, Hertzman M, et al. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 1997;58:484–91
   PubMed Web of Science ®Google Scholar
• Stahl SM. Essential psychopharmacology. Neuroscientific basis and practical applications. Cambridge: Cambridge University Press; 2000
   Google Scholar
• Owen MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305–22
   PubMed Web of Science ®Google Scholar
• Stahl SM. Basic psychopharmacology of antidepressants. Part 1. Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998;59\(Suppl 4):5–14
   Google Scholar
• Feighner JP. Trazodone, a triazolopyridine derivative, in primary depressive disorder. J Clin Psychiatry 1980;41:250–5
   PubMed Web of Science ®Google Scholar
• Fabre LF, Feighner JP. Long-term therapy for depression with trazodone. J Clin Psychiatry 1983;44:17–21
   PubMed Web of Science ®Google Scholar
• Patten SB. The comparative efficacy of trazodone and imipramine in the treatment of depression. Can Med Assoc J 1992;146:1177–82
   Web of Science ®Google Scholar
• Goldberg HL, Finnerty RJ. Trazodone in the treatment of neurotic depression. J Clin Psychiatry 1980;41:430–4
   PubMed Web of Science ®Google Scholar
• Beasley Jr CM, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991;52:294–9
   PubMed Web of Science ®Google Scholar
• Namiki M, Eiji M, Minemoto H, et al. A clinical phase III study of SME3110 (fluvoxetine maleate) in depressed patients at the Department of Internal Medicine. A double blind, comparative study with trazodone hydrochloride. J Clin Ther Med 1996;12:651–77
   Google Scholar
• Kasper S, Olivieri L, Di Loreto G, et al. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin 2005;21:1139–46
   PubMed Web of Science ®Google Scholar
• Tsutsui SA, Okuse S, Sasaki D, et al. A clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor, in the treatment of depression and depressive state. Jpn J Neuropsychopharmacol 1997;19:549–68
   Web of Science ®Google Scholar
• American Psychiatric Association. DSM-IV diagnostic and statistical manual of mental disorders, 4th edition 1994. International version with ICD-10 codes. Washington (DC): American Psychiatric Association; 1995
   Google Scholar
• Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278–96
   PubMedGoogle Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change.Br J Psychiatry 1997;134: 332–89
   Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology [revised]. Rockville, (MD): US Department of Health, Education and Welfare; 1976. p. 217–22
   Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–5
   PubMed Web of Science ®Google Scholar
• Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999;60:29–34
   PubMed Web of Science ®Google Scholar
• Perry PJ, Garvey MJ, Kelly MW, et al. A comparative trial of fluoxetine versus trazodone in outpatients with major depression. J Clin Psychiatry 1989;50:290–4
   PubMed Web of Science ®Google Scholar
• Mehtonen OP, Sǿgaard J, Roponen P, et al. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 2000;61:95–100
   PubMed Web of Science ®Google Scholar
• Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57(Suppl 2):53–62
   PubMed Web of Science ®Google Scholar
• Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999;60(Suppl 17):28–31
   PubMed Web of Science ®Google Scholar
• De Wilde J, Spiers R, Mertens C. A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression. Br J Clin Res 1997;8:23–32
   Google Scholar
• Newhouse PA, Krishnan KRR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000;61:559–68
   PubMed Web of Science ®Google Scholar
• Saletu-Zyhlarz GM, Abu-Bakr MH, Gruber G, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:249–60
   PubMed Web of Science ®Google Scholar
• Falk WE, Rosenbaum JF, Otto MW, et al. Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psychiatry Neurol 1989;2:208–14
   PubMedGoogle Scholar
• Doogan DP. Toleration and safety of sertraline: experience world-wide. Int Clin Psychopharmacol 1991;6(Suppl 2):47–56
   PubMed Web of Science ®Google Scholar
• Saletu-Zyhlarz GM, Anderer P, Arnold O, et al. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsycho-biology 2003;48:194–208
   Google Scholar
• Pohlmeier H, De Gregorio M, Sieroslawski H. Clinical data on trazodone: a review of the literature. In: Gershon et al. (Eds), Trazodone – a new broad spectrum antidepressant. Proc 11th Congr CINP, July 9–14, 1978. Amsterdam: Excerpta Medica, 1980, pp.8–26
   Google Scholar